Nexium Capsules LDA Specific Clinical Experience Investigation

NCT01729182 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 2363

Last updated 2019-08-07

No results posted yet for this study

Summary

The purpose of this investigation is to collect following data in patients given Nexium capsule (Nexium) for long term in usual-post-marketing therapy to prevention of recurrence of gastric ulcer or duodenal ulcer with Low dose Aspirin (LDA).

Conditions

  • Gastric Ulcer
  • Duodenal Ulcer

Sponsors & Collaborators

Principal Investigators

  • Shigeru Yoshida, MD · AstraZeneca

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-01-01
Primary Completion
2017-03-09
Completion
2017-03-09

Countries

  • Japan

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01729182 on ClinicalTrials.gov